Hemodynamics, fluids & transfusion
Angiotensin-II and Thromboembolic Events: A Systematic Review*
Authors' conclusion
Published evidence does not currently support or refute an association between angiotensin-II and an increased risk of venous or arterial thromboembolic events.
Study context
- Population
- Adults receiving treatment for shock7 studies (2 RCTs, 5 nonrandomised)
- Participants
- 1,461 adults
- Comparison
- Angiotensin-II vs comparator
- Outcome
- Venous and/or arterial thromboembolic events
Methodological detailsno quantitative synthesis, 1689 records screened by two independent investigators, Risk of bias assessed with RoB 2 and ROBINS-I tools
- No quantitative synthesis
- 1689 records screened by two independent investigators
- Risk of bias assessed with RoB 2 and ROBINS-I tools
Pooled result
As reported in the abstract
Thromboembolic events
Venous thromboembolic events, angiotensin-II
8.8%
Venous thromboembolic events, controls
9.4%
Arterial thromboembolic events, angiotensin-II
11.3%
Arterial thromboembolic events, controls
12.7%
Further pooled results
Total event rates (primary publications vs FDA-adjusted trial data)
- Total event rates broadly comparable with primary-publication data and FDA-adjusted data
Original publication
Angiotensin-II and Thromboembolic Events: A Systematic Review*. Crit Care Med. Published 15 October 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →